ArticleAnnals of translational medicine2020
Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Soluble B7-H6 as a Novel Diagnostic Biomarker for Post-Hepatitis B Cirrhosis: A Clinical Value Study.Journal of clinical laboratory analysis · 2026Article
- BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer.Neoplasia (New York, N.Y.) · 2025Article
- Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.Therapeutic advances in vaccines and immunotherapy · 2023Review
- Deficiency of N-linked glycosylation impairs immune function of B7-H6.Frontiers in immunology · 2023Article
- Expression and prognosis of the B7 family in acute myeloid leukemia.Annals of translational medicine · 2021Article
- Review
- Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.Oncoimmunology · 2021Article
- B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundB7-H6 is a novel co-stimulatory ligand that is detected in most malignancies. However, the significance of B7-H6 in small cell lung cancer (SCLC) remains unknown.
methodsB7-H6 expression was analyzed by immunohistochemistry (IHC) in 103 collected SCLC samples, and its association with clinicopathological characteristics and prognosis was analyzed. The 2-year survival rates were also investigated.
resultsB7-H6-positive staining was detected in 58 (56.31%) SCLC cases, and found to be localized mainly in the intracellular space of SCLC. Weak staining in lung tissues was observed in 4 (8%) cases. B7-H6 positive staining was significantly related to tumor-node-metastasis stage (P=0.028), age (P=0.001), and distant metastasis (P=0.033), whereas there was no association with smoking status, sex, mass size, limited-stage SCLC/extensive-stage SCLC, Karnofsky performance status, or nodal metastasis status. The 2-year survival rates showed that there were more patients whose survival was shorter than 2 years in the B7-H6-positive group compared with the B7-H6-negative group (P=0.042).
conclusionsOur findings suggest that B7-H6 is involved in early-stage SCLC and could serve as an early marker to predict human SCLC progression and distant metastasis. B7-H6 may be a valuable therapeutic target with potential clinical applications in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.